Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet
Solna, Sweden, September 15, 2026 — Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy. The results confirm the previously reported in…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.